157 related articles for article (PubMed ID: 9112066)
1. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
Cheymol G; Woestenborghs R; Snoeck E; Ianucci R; Le Moing JP; Naditch L; Levron JC; Poirier JM
Eur J Clin Pharmacol; 1997; 51(6):493-8. PubMed ID: 9112066
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Cheymol G; Poirier JM; Carrupt PA; Testa B; Weissenburger J; Levron JC; Snoeck E
Br J Clin Pharmacol; 1997 Jun; 43(6):563-70. PubMed ID: 9205815
[TBL] [Abstract][Full Text] [Related]
3. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol.
Stoleru L; Wijns W; van Eyll C; Bouvy T; Van Nueten L; Pouleur H
J Cardiovasc Pharmacol; 1993 Aug; 22(2):183-90. PubMed ID: 7692155
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats.
Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
Hypertens Res; 2014 Mar; 37(3):194-201. PubMed ID: 24132009
[TBL] [Abstract][Full Text] [Related]
5. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.
Himmelmann A; Hedner T; Snoeck E; Lundgren B; Hedner J
Eur J Clin Pharmacol; 1996; 51(3-4):259-64. PubMed ID: 9010695
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers.
Briciu C; Neag M; Muntean D; Vlase L; Bocsan C; Buzoianu A; Gheldiu AM; Achim M; Popa A
J Clin Pharm Ther; 2014 Oct; 39(5):535-40. PubMed ID: 24845234
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine.
Kamali F; Howes A; Thomas SH; Ford GA; Snoeck E
Br J Clin Pharmacol; 1997 Feb; 43(2):201-4. PubMed ID: 9131955
[TBL] [Abstract][Full Text] [Related]
8. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
9. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer.
Xhonneux R; Wouters L; Reneman RS; Janssen PA
Eur J Pharmacol; 1990 Jun; 181(3):261-5. PubMed ID: 1974517
[TBL] [Abstract][Full Text] [Related]
10. Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats.
Bertera FM; Del Mauro JS; Polizio AH; Chiappetta D; Taira CA; Höcht C
Naunyn Schmiedebergs Arch Pharmacol; 2012 Aug; 385(8):833-43. PubMed ID: 22566167
[TBL] [Abstract][Full Text] [Related]
11. Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat.
Schneider J; Fruh C; Wilffert B; Peters T
Pharmacology; 1990; 40(1):33-41. PubMed ID: 1970437
[TBL] [Abstract][Full Text] [Related]
12. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension.
Predel HG; Mainka W; Schillings W; Knigge H; Montiel J; Fallois J; Agrawal R; Schramm T; Graf C; Giannetti BM; Bjarnason-Wehrens B; Prinz U; Rost RE
J Hum Hypertens; 2001 Oct; 15(10):715-21. PubMed ID: 11607802
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.
Van de Water A; Xhonneux R; Reneman RS; Janssen PA
Eur J Pharmacol; 1988 Oct; 156(1):95-103. PubMed ID: 3208842
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of nebivolol.
Janssens WJ
J Pharm Belg; 1992; 47(4):323-7. PubMed ID: 1357130
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol: a third-generation beta-adrenergic blocker.
Veverka A; Nuzum DS; Jolly JL
Ann Pharmacother; 2006; 40(7-8):1353-60. PubMed ID: 16822893
[TBL] [Abstract][Full Text] [Related]
16. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.
Stoschitzky K; Stoschitzky G; Brussee H; Bonelli C; Dobnig H
Cardiology; 2006; 106(4):199-206. PubMed ID: 16679760
[TBL] [Abstract][Full Text] [Related]
17. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
[TBL] [Abstract][Full Text] [Related]
18. Influence of nebivolol on the cardiovascular hemodynamics during postural changes and isometric exercise.
Duprez D; Lefebvre R; De Backer T; De Sutter P; Trouerbach J; Clement DL
Cardiovasc Drugs Ther; 1991 Aug; 5(4):709-17. PubMed ID: 1679662
[TBL] [Abstract][Full Text] [Related]
19. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
20. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
Greven J; Gabriëls G
Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
